![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Hilditch, AA Hunt, A Travers, J Polley, GM Drew, D Middlemiss, DB Judd, BC Ross and MJ Robertson
Department of Medicinal Chemistry, Glaxo Research and Development, Ltd., Ware, Hertfordshire, England.
The antagonist activity of GR138950 (1-[[3-bromo-2-[2- [[(trifluoromethyl)sulphonyl]amino]phenyl]-5- benzofuranyl]methyl]-4- cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide) was investigated at angiotensin AT1 receptors and AT2 receptors in vitro and on blood pressure in conscious rats. GR138950 suppressed and displaced angiotensin II (AII) concentration-effect curves in the rabbit isolated aorta (pKb approximately 9.0-9.7) but had no effect against phenylephrine or serotonin induced-contractions. GR138950 competed with [3H]-AII for angiotensin AT1 receptors in rat liver membranes (pKi = 9.09). GR138950 had no apparent affinity for angiotensin AT2 receptors (bovine cerebellum; pKi < 6.0). GR138950 (1 mg/kg i.a. and p.o.) inhibited pressor responses to AII, but not phenylephrine, in conscious normotensive rats. Parallel displacements in AII dose-response curves occurred without any reduction in the maximum response to AII. The antagonist activity of GR138950 lasted for up to 24 h. GR138950 (> 0.03 mg/kg i.a., > 0.3 mg/kg p.o.) significantly reduced diastolic blood pressure (DBP) in renal artery ligated hypertensive rats. DBP was reduced maximally, 5 to 7 h after administration and the antihypertensive effect of GR138950 lasted for up to 48 h. Daily administration (5 days) of GR138950 to renal artery ligated hypertensive rats produced a sustained reduction in DBP. Acute administration of GR138950 (1 mg/kg i.a.) also significantly reduced DBP in spontaneously hypertensive rats but not in normotensive rats. Heart rate was little changed in renal artery ligated hypertensive rats, normotensive rats and spontaneously hypertensive rats. These experiments demonstrate that GR138950 is a potent, selective and specific angiotensin AT1 receptor antagonist that is orally active and reduces DBP in conscious hypertensive rats.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  A. J. Forhead and A. L. Fowden Role of angiotensin II in the pressor response to cortisol in fetal sheep during late gestation Exp Physiol, May 1, 2004; 89(3): 323 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. A. Paull, X. C. Li, D. B. Sampey, and R. E. Widdop Pharmacodynamic Contribution to the Vasodilator Effect of Chronic AT1 Receptor Blockade in SHR Hypertension, January 1, 2001; 37(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Ogino, B. Cai, A. Gu, T. Kohmoto, N. Yamamoto, and D. Burkhoff Factors contributing to pressure overload-induced immediate early gene expression in adult rat hearts in vivo Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H380 - H387. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
